Fledgling French biotech pens $128M deal for Kezar's preclinical protein degrader program (FierceBiotech) - Mar 12, 2026 - "Kezar’s program is a good fit for Paris-based Enodia, which has a platform also focused on Sec61. Specifically, Enodia has been exploring how modulating the Sec61 complex could prevent cells from producing disease-relevant proteins in order to develop a pipeline of its own small-molecule inhibitors."
Licensing / partnership • Oncology • Solid Tumor
|